Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors.

ABSTRACT:

Purpose

A growing body of evidence indicates that zoledronic acid (ZA) can improve the clinical outcome in patients with breast cancer and low estrogen levels. In the present study, we aimed to investigate the survival benefit of ZA administration in postmenopausal Korean women with breast cancer who were also receiving aromatase inhibitors.

Methods

Between January 2004 and December 2010, 235 postmenopausal breast cancer patients undergoing aromatase inhibitor therapy were investigated. All patients were postmenopausal, as confirmed by laboratory tests. Of these patients, 77 received adjuvant upfront ZA for at least 1 year in addition to conventional adjuvant treatment. The remaining 158 patients never received ZA and were treated according to the St. Gallen guidelines.

R

SUBMITTER: Ahn SG 

PROVIDER: S-EPMC4278054 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature